KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares IssuedShares RepurchasedShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Change in Accured Expenses (2016 - 2026)

Emergent BioSolutions has reported Change in Accured Expenses over the past 17 years, most recently at -$20.2 million for Q1 2026.

  • For Q1 2026, Change in Accured Expenses rose 37.27% year-over-year to -$20.2 million; the TTM value through Mar 2026 reached -$5.3 million, down 139.55%, while the annual FY2025 figure was -$17.3 million, 240.65% down from the prior year.
  • Change in Accured Expenses for Q1 2026 was -$20.2 million at Emergent BioSolutions, down from $9.7 million in the prior quarter.
  • Over five years, Change in Accured Expenses peaked at $37.1 million in Q2 2024 and troughed at -$61.0 million in Q4 2022.
  • A 5-year average of -$8.7 million and a median of -$700000.0 in 2025 define the central range for Change in Accured Expenses.
  • Biggest five-year swings in Change in Accured Expenses: tumbled 503.97% in 2022 and later soared 4022.22% in 2024.
  • Year by year, Change in Accured Expenses stood at -$61.0 million in 2022, then rose by 10.0% to -$54.9 million in 2023, then soared by 140.44% to $22.2 million in 2024, then tumbled by 56.31% to $9.7 million in 2025, then plummeted by 308.25% to -$20.2 million in 2026.
  • Business Quant data shows Change in Accured Expenses for EBS at -$20.2 million in Q1 2026, $9.7 million in Q4 2025, and -$700000.0 in Q3 2025.